What monitoring is recommended when initiating or changing the dose of a RASi in a patient at risk for hyperkalemia?
In patients at risk for hyperkalemia, measuring serum potassium before and at 1 2 weeks after initiation of RASi is recommended, based on expert opinion. Moreover, patients should be monitored for symptomatic hypotension, hyperkalemia, and serum creatinine within 2 4 weeks after initiating or changing the dose of the drug, with the time interval depending on baseline BP, serum creatinine, and serum potassium.